The Net Margin of Agenus Inc (AGEN) is
0.10%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
0.10%
|
| 2024-12-31 |
-219.61%
|
| 2023-12-31 |
-157.22%
|
| 2022-12-31 |
-224.51%
|
| 2021-12-31 |
-8.09%
|
| 2020-12-31 |
-205.19%
|
| 2019-12-31 |
-71.75%
|
| 2018-12-31 |
-434.13%
|
| 2017-12-31 |
-281.48%
|
| 2016-12-31 |
-562.60%
|
| Ticker |
Name |
Value |
|
ARDX
|
Ardelyx, Inc.
|
-15.12%
|
|
HARP
|
Harpoon Therapeutics Inc
|
-212.19%
|
|
KDNY
|
Chinook Therapeutics Inc
|
-3065.68%
|
|
950200.KQ
|
Psomagen Inc
|
-5.04%
|
|
950220.KQ
|
Neoimmunetech Inc
|
-33533.01%
|
|
ANAB
|
AnaptysBio, Inc.
|
246.96%
|
|
GTHX
|
G1 Therapeutics Inc
|
-58.13%
|
|
MRNA
|
Moderna, Inc.
|
-145.16%
|
|
SURF
|
Surface Oncology Inc
|
-211.95%
|
|
ACIU
|
AC Immune AG
|
-1971.65%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
31.41%
|
|
SQZ
|
SQZ Biotechnologies Co
|
-369.98%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
-3733.25%
|
|
AMGN
|
Amgen Inc
|
20.98%
|
|
JNCE
|
Jounce Therapeutics Inc
|
-62.10%
|
|
KALV
|
KalVista Pharmaceuticals, Inc.
|
-223.16%
|
|
ABBV
|
AbbVie Inc.
|
6.91%
|
|
BCYC
|
Bicycle Therapeutics PLC
|
-301.66%
|
|
CTMX
|
CytomX Therapeutics, Inc.
|
-22.79%
|
|
MTEM
|
Molecular Templates Inc
|
-14.18%
|
|
XBIT
|
XBiotech Inc
|
-820.45%
|
|
DTIL
|
Precision Biosciences, Inc
|
-133.45%
|
|
XOMA
|
XOMA Royalty Corporation
|
60.81%
|
|
ALBO
|
Albireo Pharma Inc
|
-83.86%
|
|
MREO
|
Mereo BioPharma Group PLC
|
-8375.60%
|
|
RAPT
|
RAPT Therapeutics, Inc
|
-5479.74%
|
|
RIGL
|
Rigel Pharmaceuticals, Inc.
|
124.72%
|
|
SESN
|
Sesen Bio Inc
|
-1.27%
|
|
ACET
|
ADICET Bio, Inc.
|
-279.27%
|
|
CNTG
|
Centogene NV
|
-73.21%
|
|
GILD
|
Gilead Sciences, Inc.
|
28.90%
|
|
IDYA
|
IDEAYA Biosciences, Inc.
|
-51.99%
|
|
KPTI
|
Karyopharm Therapeutics Inc.
|
-134.21%
|
|
PSTX
|
Poseida Therapeutics Inc
|
-190.76%
|
|
SELB
|
Selecta Biosciences Inc
|
31.94%
|
|
SYRS
|
Syros Pharmaceuticals Inc
|
-1656.34%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
32.94%
|